Beyaz

Introduction

FDA-approved 09/2010.

• a combination of Yaz (monophasic oral contraceptive) & levomefolate Ca+2 (a folate)

Indications

• to raise folate levels for the purpose of reducing risk of neural tube defect in a pregnancy conceived while taking Beyaz or shortly after discontinuing the it

Pharmacokinetics

• increases folate levels in women
  • folate levels remained elevated for several weeks following discontinuation of Beyaz

Notes

• it seems as if the oral contraceptive is effective, there is little risk of neural tube defects in a fetus

More general terms

• monophasic oral contraceptive